Cadila Healthcare Limited is a leading Indian pharmaceutical company with a global presence. The company is engaged in the research, development, manufacture and marketing of a wide range of pharmaceutical products. Cadila Healthcare has a strong focus on the domestic market and is one of the leading players in the Indian pharmaceutical market. The company has a diversified product portfolio and offers a wide range of products in the therapeutic areas of cardiovascular, central nervous system, gastrointestinal, anti-infectives, diabetology, oncology, pain management and respiratory. Cadila Healthcare has a strong research and development infrastructure and has a dedicated team of scientists working on the development of new products and formulations. The company has a state-of-the-art manufacturing facility and a well-established marketing and distribution network. Cadila Healthcare is listed on the Bombay Stock Exchange and the National Stock Exchange of India.
Number of employees: 10,001-25,000
Business strategy: Cadila Healthcares business strategy is focused on the domestic market and the company is one of the leading players in the Indian pharmaceutical market. The company has a diversified product portfolio and offers a wide range of products in the therapeutic areas of cardiovascular, central nervous system, gastrointestinal, anti-infectives, diabetology, oncology, pain management and respiratory. Cadila Healthcare has a strong research and development infrastructure and has a dedicated team of scientists working on the development of new products and formulations. The company has a state-of-the-art manufacturing facility and a well-established marketing and distribution network.
Future outlook: Cadila Healthcare is well-positioned to grow in the domestic market and consolidate its position as a leading Indian pharmaceutical company. The company is expected to benefit from the growing demand for pharmaceutical products in India. Cadila Healthcare is also expected to benefit from the growing trend of outsourcing of pharmaceutical research and development by multinational companies.
Exchange traded: BSE: 500257, NSE: CADILAHC
Website: http://www.cadilapharma.com